Sickle cell pain includes three types: acute recurrent painful crises, chronic pain syndromes and neuropathic pain. The acute painful crisis is the hallmark of the disease and the most common cause of hospitalization and treatment in the Emergency Department. It evolves through four phases: prodromal, initial, established and resolving. Each acute painful episode is associated with inflammation that worsens with recurrent episodes, often culminating in serious complications and organ damage such as acute chest syndrome, multi-organ failure and sudden death. Three pathophysiologic events operate in unison during the prodromal phase of the crisis: vaso-occlusion, inflammation and nociception. Aborting the acute painful episode at the prodromal phase could potentially prevent or minimize tissue damage. Our hypothesis is that managing these events with hydration, anti-inflammatory drugs, aggressive analgesia and possibly vasodilators could abort the crisis and prevent or minimize further damage. Chronic pain syndromes are associated with or accompany avascular necrosis and leg ulcers.
Introduction
Sickle cell disease (SCD) has been primarily considered a disease of children with a few patients surviving to adulthood. Between 1910 and 1950 the median survival of patients with SCD was less than 20 years of age.
1 Sudden death occurred in about 41% of the patients while 29% deaths occurred within 24 hours after the onset of painful crises 2 . By 1980 50% of children survived to 20 years of age and by 2009 survival to age 20 years increased to 85% of children 2 .
However, if we rewind the clock of time by over a century when SCD was first described in the US, we find that the first four SCD patients reported were adults with leg ulcers [3] [4] [5] [6] . Prior to 1910 there were observations among adult African slaves suggestive of sickle cell disease with immunity to malaria and high prevalence of leg ulcers 7 . Moreover autopsy on a slave with history of fever and respiratory illness in 1846 showed absence of the spleen 8 . The inevitable question then, is where were the children with SCD in the US before 1910? There must have been children with SCD. The patient reported by Cook and Meyer 5 gave family history of brothers and sisters who died in early life of a disease associated with grave anemia. These children must have lived, suffered and died prematurely, the dark side of the discovery of sickle cell anemia in the US 9
. It was not until the early 1930's that children with SCD were recognized.
Sickle Cell Pain between 1930 and 1960
Between 1930 and 1960 the emphasis was on studying the basic science of SCD. This period witnessed quantum leaps in defining the specific molecular signature of SCD with the advent of Hb electrophoresis [10] [11] [12] . Diggs and Chang 13 suggested that the painful sickle cell crises are the For personal use only. on September 12, 2018. by guest www.bloodjournal.org From result of blockage of the small blood vessels by the abnormal RBCs. The major therapeutic goal was to identify methods to prevent the blockage of small blood vessels. Diggs realized that pain was a major problem among patients with sickle cell anemia and used papaverine and acetaminophen to treat it 14 . A number of futile therapeutics were introduced, including liver extract, whole liver diet, spleen diet, iron, arsenic, calcium, iodides, alkalis, blood transfusion, urea, cyanate and hyperbaric oxygen [15] [16] [17] [18] [19] .
In the 1960's adult patients with severe pain not responsive to oral analgesics were treated in the Emergency Departments (ED). At that time the only parenteral opioids approved by the FDA for pain management were meperidine and fentanyl citrate. The latter, however, was approved for surgical use only and meperidine became the drug of choice to treat severe sickle cell pain.
Follow-up studies of the Multicenter Study of Hydroxyurea (MSH) in sickle cell anemia showed that meperidine was most often used for painful crises in the ED and hospital and short-acting oxycodone with acetaminophen most often used for pain at home.
20,21
Sickle This policy conveyed the message to providers that morphine is the only opioid to be used to treat acute painful crises. The meperidine phobia emerged because normeperidine, the major metabolite of meperidine is neurotoxic and may lower the seizure threshold especially in patients with impaired renal function. There are no controlled trials to compare meperidine with morphine in patients with sickle cell disease. The incidence of seizures related to the use of meperidine in patients with SCD varies between 1% and 12% [24] [25] [26] .
Although there are no controlled trials to compare the safety and efficacy of different opioids in the management of acute sickle cell crises, patient safety can be maximized by obtaining a detailed history; understanding opioid pharmacology, mechanism of action and side effects;
carefully monitoring patients; and individualizing care. Meperidine should not be used to treat acute sickle cell pain in patients with impaired renal function, history of seizure disorder, or those on serotoninergic medications.
Ironically it turned out that morphine is not a panacea in terms of its own side effects. These include nausea, vomiting, pruritus, constipation, mental changes, tolerance, dependence, hyperalgesia and addiction. Morphine also causes seizures with a reported prevalence of 1.2% if given in sufficiently large doses 27 . Morphine is the most histaminergic opioid 28 and is associated with severe pruritus in some patients. Moreover, there have been reports of death with the use of morphine in patients with SCD 29, 30 . The use of morphine in patients with SCD seems to be associated with acute chest syndrome [31] [32] [33] . In addition morphine and morphine-6-For personal use only. on September 12, 2018. by guest www.bloodjournal.org From glucoronide, a major metabolite of morphine, are both excreted in the urine and care has to be taken if given to patients with renal failure.
Morphine stimulates diverse neural and non-neural molecular targets (see supplemental Table   1S ). Morphine induces expression of platelet derived growth factor-BB (PDGF-BB) in human brain and umbilical vein endothelial cells and PDGF receptor-β (PDGFR-β) expression in pericytes 34, 35 . Morphine also activates vascular endothelial growth factor receptor-2 (VEGFR2), PDGFR-β, sphingosine 1 phosphate receptor 3 (S1P3R), mitogen activated protein kinase/extracellular signal related kinase (MAPK/ERK) and cycloxygenase-2 (COX-2) in endothelial cells and the central nervous system [35] [36] [37] [38] [39] . Together, these growth factor-like activities of morphine stimulate vascular permeability, endothelial activation, vascular smooth muscle cell pathology, analgesic tolerance and kidney disease. Studies in the transgenic sickle mouse showed that morphine amplifies renal pathology, stimulates albuminuria and impairs renal function 36, [40] [41] [42] . These morphine-induced signaling mechanisms suggest that pulmonary edema may perhaps be due to increased vascular permeability in patients receiving morphine and hydrated or overhydrated at the same time. Alternatively, it could be due to undiagnosed pulmonary hypertension that can lead to pulmonary edema with aggressive hydration. We speculate that increased vascular permeability induced by morphine may be associated with hemorrhagic stroke in SCD.
Considering the endothelial and neural-specific effects, morphine use needs to be critically evaluated for their contribution to organ disease.
Presently several opioids are available for parenteral use as needed including morphine, codeine, meperidine, hydromorphone, oxymorphone, levorphanol, methadone, and fentanyl. Choice of suggestive of a prodromal phase of 1 to 2 days in 59 out of 102 (58%patients with SCD) during a questionnaire study. Reported symptoms included numbness, paresthesia or aches in the areas that subsequently became painful. The duration of the prodromal phase was up to one or two days. The phases were called prodromal, initial, established, and resolving phases (Figure 1 ).
Beyer et al 50 and Jacob et al 51 reported the evolution of painful crises along similar phases in children.
The presence of phases of the crises allows providers to monitor the progress of the crisis and manage it according to rational basis and avoid the conflicts that often arise about the authenticity of pain. Fig 1 and Table1 show a number of changes in objective signs during the evolution of the crisis. These changes, however, can be appreciated if the parameters are determined serially and, more importantly, if they are compared to steady state values 52,53
Consequences of the acute painful crisis
The acute painful crisis is associated with serious complications of the disease, most frequently occurring between days 1-5. About 50% of reported cases of acute chest syndrome occur following hospitalization with a painful crisis 54 . Acute multiorgan failure 55 and sudden death 56 also have been reported during painful crises.
Resolution of the painful crisis is associated with rebound thrombocytosis, elevated levels of fibrinogen, orosomucoid, decreased RBC deformability and increased plasma viscosity, all predisposing to a hypercoagulable state that may cause recurrence of the crisis (Fig 1 and Table   1 ). In order to support this hypothesis we followed patients longitudinally following discharge
For personal use only. on September 12, 2018. by guest www.bloodjournal.org From from the hospital to determine how often patients are readmitted after discharge. We found that about 20% of the patients who were discharged from the hospital after the resolution of a crisis had recurrent crises that required treatment with parenteral opioids in the ED or hospital within one week after discharge (Table 2) . 46 A painful crisis seems to be a risk marker for a subsequent crisis; however some patients, especially children, have a pain-free-period of variable duration before the onset of another crisis (Fig 2) . Others continue to have pain. According to the Pain In Sickle Cell Epidemiology Study (PISCES) adult patients reported SCD pain at home on about 55% of the 31,017 days 57 while children reported SCD pain at home on about 9% of the1515 days surveyed 58, 59 . In MSH at-home analgesics were used for SCD pain on 40% of diary days and 80% of two-week follow-up periods, with short-acting oxycodone and acetaminophen being the most frequently used analgesics 21, 60 . Descriptors and location of pain at home were similar to those during hospitalization but milder. Importantly, at home patients preferred to treat pain with short-acting opioids rather than the controlled-release opioids. Moreover, those who take controlled release opioids with short acting opioids for breakthrough pain experience frequent attacks of breakthrough pain resulting in the consumption of relatively large amounts of shortacting opioids. In addition, patients prefer to be treated in the day unit rather than the ED to avoid long hours of waiting. Treatment of patients in the day unit with parenteral short-acting opioids decreased the frequency of hospital admissions and ED visits 61 .
In order to determine the actual pattern of hospital admissions of patients with SCD and the causes of frequent hospital readmissions and their prognostic significance a prospective longitudinal and observation cohort study of all adult patients with SS admitted to one institution between January 1998 and December 2002 was conducted 43 . Analysis of the data showed that:
1) about 95% of all the 1540 admissions of 136 patients were for acute painful crises; 2) the For personal use only. on September 12, 2018. by guest www.bloodjournal.org1 0 intensity of pain score decreased significantly during the first 4 days of hospital admission from an average of 8.7 ±1.17 to 7.5 ± 1.00 (P < 0.001) and then reached a plateau of 7.4 until discharge. (Fig. 3) ; 3) the mean score of pain intensity was >7 throughout the hospital stay; 4) about 50% of hospital admitted patients for acute painful episodes were readmitted within 1 month after discharge, and about 16% of all admissions were readmitted within 1 week after discharge (Table 3 ). The major cause of hospital readmission was the same acute sickle cell pain that was not controlled with analgesics at home or in the ED. Withdrawal syndrome was the cause of readmission only in five patients who were readmitted collectively 46 times (about 7% of all readmissions) within one week after discharge. About 10% of children and about 50% of adults with sickle cell disease continue to have pain between painful episodes. The severity and duration of each pain event between crises varies among individuals. Thus the hallmark of sickle cell disease seems to be continuous acute pain the severity of which varies from severe to mild or moderate. When the pain is severe it requires treatment in the ED or in the hospital with parenteral opioids and when it is mild or moderate it is treated at home with oral analgesics. The transition from acute painful crises with no pain in between to acute painful crises with mild or moderate pain in between is age dependent. Thus the majority of children are pain free between recurrent painful episodes (Fig 2) and about 50% of adult continue to have mild to moderate pain between relapsing crises (Fig 4) . The opinion of two of the authors (SKB & PAG) based on their experience is that descriptors of the pain are mostly the same as in acute crisis and that short acting opioids are preferred for analgesia by the majority of adult patients. These opinions are further supported by a follow-up study of MSH showing that at home analgesics were used on 40% of diary days and 80% of two-week followup periods, with oxycodone and codeine the most frequently used analgesics 21 .
Pathophysiology of acute pain
The pathophysiology of acute pain in general has been extensively reviewed in major textbooks on pain medicine [66] [67] [68] . The reader is advised to consult these references for more details. This section will discuss the highlights of this subject.
Vaso-occlusion leads to hypoxia, ischemia, and eventually tissue damage followed by chronic vascular inflammation underlying many features of sickle cell pain [69] [70] [71] 
Central Sensitization and Neuroplasticity
Central sensitization is the process by which excessive nociceptive signals bombarding the CNS from the periphery cause changes both in the spinal cord and the brain that result in continuous amplification of pain sensation [74] [75] [76] . "rewiring" of the brain in patients who have persistent severe pain. Alternative circuits of pain transmission and remapping of functional connections 78 occur in the brains of these patients. The best example of this phenomenon in patients with SCD is that severe pain persisted for several weeks or months even in those patients who were cured of sickle cell anemia after successful bone marrow transplantation 79 . It takes a relatively long time to reset the "wiring" of the brain back to normal in these patients. Another possible explanation for this delay in pain resolution is that it took this long for target sites to heal its regional tissue damage, blood vessel damage, or peripheral nerve damage.
Chronic Pain
Chronic pain is often defined as pain that persists for 3 or more months. Sources of chronic pain in sickle cell disease include bone infarction, avascular necrosis of joints, back pain from disk protrusion into vertebral bodies, leg ulcers, and chronic osteomyelitis. 80 The descriptors of the pain of these conditions are different from the pain associated with the acute painful crisis or the pain that persists between crises. The pain of these syndromes is usually treated with long-acting or control-release opioids with less use of short-acting opioids for breakthrough pain in contrast to the case in the persistent pain between acute painful crises. 81 Moreover, these pain syndromes rarely require hospital admission except when a painful crisis is superimposed on the chronic pain or if the underlying condition is associated with severe infection that requires parenteral antibiotics as may happen in leg ulcers.
We and others previously described a second type of chronic pain in SCD. 80, [82] [83] [84] It is intractable chronic pain without obvious pathology where the only complaint is the patient's self-report of pain that does not go away. We think we were adopting and borrowing concepts from other pain
For personal use only. on September 12, 2018. by guest www.bloodjournal.org1 5 disciplines. We need to reconsider this. SCD does have obvious pathology documented by the presence of the sickle gene and sickle Hb which are pathologic. It seems we were referring to the persistent pain between crises as chronic pain without pathology.
Neuropathic pain
Neuropathic pain is usually described as numb, tingling, lancinating, spontaneous, shooting or paroxysmal in nature associated with a sensation of pins and needles, hyperalgesia and allodynia (pain due to ambient non-noxious stimuli). 80, 83 Its severity is also enhanced by exposure to either cold or heat. This pain could be secondary to nerve injury or nerve dysfunction whether peripherally or centrally. Anecdotally, neuropathic pain in SCD may be due to tissue damage following vaso-occlusion of blood vessels of nerves (vasa vasorum). Clinically it is characterized by numbness of the chin with mandibular bone pain speculated to result from nerve ischemia or compression due to mandibular bone infarction. Most of the reported cases occurred during painful sickle crises and resolved after the resolution of the crisis.
It is more common in females and was bilateral in one patient. Neuropathic pain that is often associated with persistent acute or chronic pain has not been well studied in patients with SCD to date.
For personal use only. on September 12, 2018. by guest www.bloodjournal.org . Elevated levels of Substance P in the serum of patients with SCD and increased expression of Substance P in the skin of sickle mice support the existence of nociceptor sensitization in SCD.
Redefining Sickle Cell Pain
Although the molecular pathophysiology of SCD is well understood, the management of sickle cell pain, its hallmark, is an embarrassing failure. Our perspectives redefine sickle cell pain and its unique features based on available data and the experience of experts in the field that has accumulated since 1910. This redefinition may reveal new avenues to improve our understanding and management of this complex pain syndrome. Our knowledge of sickle cell pain that evolved over the last 102 years suggests that the hallmark of SCD is acute pain that waxes and wanes, relapses and remits in a recurrent and unpredictable fashion. When severe it is the acute painful crisis that requires treatment with parenteral analgesics in the ED or hospital. When mild or moderated it is the residual or persistent acute pain between two subsequent acute painful episodes. This explains why patients are often readmitted after discharge, why they prefer using short-acting analgesics and why they are treated in the day unit or ED frequently with short acting opioids between hospital admissions. The use of "chronic sickle cell pain" should be limited to the chronic pain syndromes mentioned above.
Pain-free intervals are longer for younger than for older patients with SCD. Pain-free intervals shorten with aging. For personal use only. on September 12, 2018. by guest www.bloodjournal.org From
New Approach to Therapy
Our hypothesis is that acute painful crisis treated aggressively at its onset; its outcome would be of shorter duration with fewer complications. Unfortunately, the end of an acute sickle cell painful crisis at the present is a fuzzy point in time. Discharge from the ED or hospital does not necessarily indicate the end of the crisis. It is an arbitrary point that depends on several factors that are not based on the individual status of the patient but subscribes to insurance coverage, hospital policy and the attitude of the providers. Table 4 lists the approaches for the treatment of SCD and its complications 100 . The ultimate goal is to achieve a cure. Short of that preventing the painful crisis with agents that induce the production of Hb F is possible and short of that aborting the painful crisis is highly desirable. A triad of pathophysiologic factors initiates the acute painful crisis: vaso-occlusion, inflammation and nociception. Each painful crisis is associated with residual inflammatory damage that accumulates with recurrent crises culminating in organ dysfunction and organ failure. The rational approach to abort a crisis is to treat it as early as possible, preferably at the prodromal phase, where tissue ischemia and inflammation are in their early stages 101 (Fig 5) . The goal of management at this phase is a trial of anti-vaso-occlusive therapy akin to therapy of ischemic stroke in adults in the general population 102, 103 and to the treatment of acute myocardial infarction (MI) 104, 105 . The standard of care of ischemic stroke and MI is to give tissue plasminogen Activator (tPA), a protein that breaks down thrombi or clots, within a few hours after the onset of signs and symptoms in order to restore perfusion. Beyond that tPA will not be as effective. Anti-vaso-occlusive therapy to abort a crisis at the prodromal stage should include a trial of hydration, anti-inflammatories, analgesics and, possibly, vasodilators. Patients with SCD could be counseled and trained to treat themselves at home as soon as they feel an impending crisis. Nitric oxide would be the ideal vasodilator for self-1 9 administration at home. Gladwin et al showed that NO in the hospital is not effective in reducing the hospital length of stay of patients with painful crises. 106 Administration of NO in the ED, however, was effective in aborting crisis in some patients. 107, 108 It is probable that shifting the utilization of NO to the left (at home) rather than to the right (Hospital) is the right way to go.
Moreover blood transfusion or vigorous hydration at the prodromal phase may be effective in aborting the crisis. Sobota et al reported that transfused pediatric patients with crisis were readmitted less frequently to the hospital than otherwise. 65 The combination of NO and blood transfusion/hydration in the prodromal phase would restore perfusion and prevent or minimize damage due to hypoxia, the addition of anti-inflammatories would prevent or minimize damage due to inflammation and, most importantly, aggressive management of pain may prevent central sensitization and "rewiring" of the brain.
Currently, patients with acute painful crisis receive treatment about 2-3 days after the onset of the early prodromal signs and symptoms of the crisis. By that time irreversible tissue damage is well-established and difficult to reverse. This has to change. The rational therapy of acute sickle cell pain must be actively based on its own mechanistic pathophysiology and not by the passive adoption of guidelines of other pain syndromes. For
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